Cost-effectiveness of linezolid vs. vancomycin in nosocomial pneumonia due to suspected methicillin-resistant Staphylococcus aureus in France

被引：0
|
作者：
De Cock, E. [1 ]
Timsit, J. F. [2 ]
Carlet, J. [3 ]
Leroy, O. [4 ]
Wolff, M. [5 ]
Levrat, F. [6 ]
机构：
[1] United BioSource Corp, Barcelona, Spain
[2] Hop Albert Michallon, Grenoble, France
[3] Grp Hosp St Joseph, Paris, France
[4] Hop Guy, Tourcoing, France
[5] Hop Bichat Claude Bernard, F-75877 Paris 18, France
[6] Pfizer, Paris, France
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A439 / A439
页数：1
相关论文
共 50 条
  • [21] Linezolid vs vancomycin -: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia
    Wunderink, RG
    Rello, J
    Cammarata, SK
    Croos-Dabrera, RV
    Kollef, MH
    CHEST, 2003, 124 (05) : 1789 - 1797
  • [22] Early Microbiological Response to Linezolid vs Vancomycin in Ventilator-Associated Pneumonia Due to Methicillin-Resistant Staphylococcus aureus
    Wunderink, Richard G.
    Mendelson, Meryl H.
    Somero, Michael S.
    Fabian, Timothy C.
    May, Addison K.
    Bhattacharyya, Helen
    Leeper, Kenneth V., Jr.
    Solomkin, Jospeh S.
    CHEST, 2008, 134 (06) : 1200 - 1207
  • [23] Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study
    Wunderink, Richard G.
    Niederman, Michael S.
    Kollef, Marin H.
    Shorr, Andrew F.
    Kunkel, Mark J.
    Baruch, Alice
    McGee, William T.
    Reisman, Arlene
    Chastre, Jean
    CLINICAL INFECTIOUS DISEASES, 2012, 54 (05) : 621 - 629
  • [24] Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis
    Wang, Yan
    Zou, Yamin
    Xie, Jiao
    Wang, Taotao
    Zheng, Xiaowei
    He, Hairong
    Dong, Weihua
    Xing, Jianfeng
    Dong, Yalin
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (01) : 107 - 115
  • [25] Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis
    Yan Wang
    Yamin Zou
    Jiao Xie
    Taotao Wang
    Xiaowei Zheng
    Hairong He
    Weihua Dong
    Jianfeng Xing
    Yalin Dong
    European Journal of Clinical Pharmacology, 2015, 71 : 107 - 115
  • [26] Comparison of Linezolid and Vancomycin for Methicillin-Resistant Staphylococcus aureus Pneumonia: Institutional Implications
    Tong, ManShan C.
    Wisniewski, Christopher S.
    Wolf, Bethany
    Bosso, John A.
    PHARMACOTHERAPY, 2016, 36 (07): : 731 - 739
  • [27] Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia
    Thamlikitkul, Visanu
    Tongsai, Sasima
    CHEST, 2012, 142 (01) : 269 - 270
  • [28] An economic model comparing linezolid and vancomycin for treatment of confirmed methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
    Patel, Dipen A.
    Shorr, Andrew F.
    Chastre, Jean
    Niederman, Michael
    Simor, Andrew
    Stephens, Jennifer M.
    Bhatt, Gaurang
    Charbonneau, Claudie
    Gao, Xin
    Nathwani, Dilip
    PHARMACOTHERAPY, 2013, 33 (10): : E214 - E214
  • [29] Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus
    Patel, Dipen A.
    Shorr, Andrew F.
    Chastre, Jean
    Niederman, Michael
    Simor, Andrew
    Stephens, Jennifer M.
    Charbonneau, Claudie
    Gao, Xin
    Nathwani, Dilip
    CRITICAL CARE, 2014, 18 (04)
  • [30] Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus
    Dipen A Patel
    Andrew F Shorr
    Jean Chastre
    Michael Niederman
    Andrew Simor
    Jennifer M Stephens
    Claudie Charbonneau
    Xin Gao
    Dilip Nathwani
    Critical Care, 18
12345